Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

ISRCTN ISRCTN19844007
DOI https://doi.org/10.1186/ISRCTN19844007
Secondary identifying numbers N0205168926
Submission date
29/09/2006
Registration date
29/09/2006
Last edited
17/05/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr A Chesser
Scientific

Consultant Nephrologist
Renal Office
Royal London Hospital
Whitechapel
London
E1 1BB
United Kingdom

Phone +44 (0)20 7377 7366
Email alistair.chesser@bartsandthelondon.nhs.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleUse of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis
Study objectivesTo quantify the effect of on-line mid-dilution haemodiafiltration on the use of erythropoietin for anaemia management in patients with end-stage renal disease compared to the technique of conventional haemodialysis.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedAnaemia
InterventionNot provided at time of registration
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Erythropoietin
Primary outcome measureControl of haemoglobin and use of erythropoietin
Secondary outcome measuresNot provided at time of registration
Overall study start date27/07/2005
Completion date31/07/2007

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants80
Key inclusion criteriaNot provided at time of registration
Key exclusion criteriaNot provided at time of registration
Date of first enrolment27/07/2005
Date of final enrolment31/07/2007

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Royal London Hospital
London
E1 1BB
United Kingdom

Sponsor information

Record Provided by the NHSTCT Register - 2006 Update - Department of Health (UK)
Government

The Department of Health, Richmond House, 79 Whitehall
London
SW1A 2NL
United Kingdom

Phone +44 (0)20 7307 2622
Email dhmail@doh.gsi.org.uk
Website http://www.dh.gov.uk/Home/fs/en

Funders

Funder type

Government

Barts and The London NHS Trust (UK)

No information available

NHS R&D Support Funding (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

17/05/2017: No publications found, verifying study status with principal investigator.